Maze Therapeutics Director Cashes Out in Major Stock Sale!

New insider activity at Maze Therapeutics, Inc. ( (MAZE) ) has taken place on September 16, 2025.

Director Richard Scheller has recently sold 20,744 shares of Maze Therapeutics, Inc. stock, amounting to a total transaction value of $463,835.

Recent Updates on MAZE stock

Maze Therapeutics, Inc. has seen a series of price target increases from various analysts following the release of promising Phase 1 trial results for its drug candidate MZE782. Guggenheim raised its price target due to the clinical results showing a significant increase in urinary Phe data, suggesting a superior profile compared to competitors. H.C. Wainwright also increased its price target, citing the robust pharmacodynamics signal of MZE782, which exceeds benchmarks and indicates best-in-class potential for treating phenylketonuria (PKU). BTIG raised its target based on the Phase 1 data exceeding expectations and increasing the probability of success for MZE782 in PKU and chronic kidney disease (CKD). Similarly, Leerink adjusted its price target upwards due to the first-in-human data supporting a best-in-class profile and increased probability-of-success estimates for MZE782.

Spark’s Take on MAZE Stock

According to Spark, TipRanks’ AI Analyst, MAZE is a Neutral.

Maze Therapeutics shows strong financial performance with significant revenue and cash flow improvements, yet the negative equity presents a substantial risk. Technical indicators suggest potential weakness in stock momentum, and lack of valuation metrics prevents a comprehensive assessment. Overall, the stock’s strengths in financial growth are tempered by balance sheet risks and technical analysis concerns.

To see Spark’s full report on MAZE stock, click here.

More about Maze Therapeutics, Inc.

YTD Price Performance: 45.77%

Average Trading Volume: 319,173

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.02B